Tag Archives: Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (LXRX) Receives a Hold from Needham

In a report released today, Alan Carr from Needham assigned a Hold rating to Lexicon Pharmaceuticals (LXRX – Research Report). The company’s shares closed last Thursday at $1.95. According to TipRanks.com, Carr is a 2-star analyst with an average return

Needham Gives a Hold Rating to Lexicon Pharmaceuticals (LXRX)

In a report released today, Alan Carr from Needham assigned a Hold rating to Lexicon Pharmaceuticals (LXRX – Research Report). The company’s shares closed last Monday at $2.26. According to TipRanks.com, Carr is a 1-star analyst with an average return

Lexicon Pharmaceuticals (LXRX) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) yesterday and set a price target of $13.00. The company’s shares closed last Monday at $2.03, close to its 52-week low of $1.13. According to

Lexicon Pharmaceuticals (LXRX) Gets a Buy Rating from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) yesterday and set a price target of $17.00. The company’s shares closed last Monday at $4.41. According to TipRanks.com, Moussatos is ranked 0 out of

Wedbush Sticks to Its Buy Rating for Lexicon Pharmaceuticals (LXRX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $17.00. The company’s shares closed last Monday at $3.51. According to TipRanks.com, Moussatos has currently no stars on

Wedbush Reiterates Their Buy Rating on Lexicon Pharmaceuticals (LXRX)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $3.35. According to TipRanks.com, Moussatos ‘ ranking